UK companies in the news:

#AAS #ACSO #ART #BIG #BUR #BVXP #CRCL #DEBS #FAB #FAS #GDR #GMR #GSK #HICL #LST #PAY #PTSB #RTW #TEAM #TENG

Head to Sharesify.com for news, views and analysis

UK companies in the news:

#AMCO #AZN #BGEU #CHAR #COIL #CTPE #FOG #GBG #GSK #HRI #IMM #MTLN #PMG #PTEC #SEE #SNRE #WKS

Head to Sharesify.com for news, views and analysis

UK companies in the news:

#AFC #APN #BAG #CASP #CHRT #DFCH #EEE #FIPP #FUM #GSF #GSK #JUST #PEY #PGH #QED #QHE #RTC #SAV #SLP #SPI #TGA

Head to Sharesify.com for news, views and analysis

Alfasigma claims early FDA nod for ex-GSK liver drug Alfasigma has claimed the first approval, in the US, for linerixibat, a drug for liver disease PBC licensed from GSK for $690m a few days ago.

The #FDA has approved #Alfasigma's #primarybiliarycholangitis (PBC) therapy #linerixibat, just days after the company licensed it from #GSK in a deal worth up to $690 million.

pharmaphorum.com/news/alfasig...

Meningitis outbreak in UK prompts call to widen vaccination A UK patient group is calling for changes to the decade-old meningitis vaccination programme, after an outbreak in Kent killed two young people

#Meningitis #UK #meningitisvaccination #meningitisvaccinationprogramme #Kent #meningitisB #MenB #meningitisVaccination #GSK #Bexsero #NHS #MenBstrains #MeningitisNOW #NoPlanBforMenB #MenBboosterprogramme #MenBvaccine #MenBdisease #UKHealthSecurityAgency #UKHSA #publichealth
zurl.co/xuNAv

Pharmalittle: We're reading about Trump's drug pricing moves, a GSK asthma drug, and more The White House is looking to intensify its pressure campaign on Congress to pass legislation to codify a “most-favored nation” drug pricing policy

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about Trump’s drug pricing moves, a GSK asthma drug, and more news.. statnews.com/pharmalot/20... #pharma #Trump #asthma #HIV #GSK #Sanofi

GSK grows pipeline with 35Pharma takeover, Frontier deal GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.

#GSK #35Pharma #pulmonaryarterialhypertension #PAH #heartfailure #FrontierBio #pharmalicensing #LukeMiels #siRNAtherapeutics #FrontierBiotech #HS235 #phase1 #clinicaltrials #heartfailurewithpreservedejectionfraction #HFpEF #bestinclasstherapy #activindirectedtherapy #INDstudies
zurl.co/9nkDQ

Asthma patients suffered as GSK pursued 'egregious' price hikes, senator says After GSK replaced a popular asthma inhaler with an identical product at a higher price, families reported substantial financial and treatment problems, according to a new report.

Asthma patients suffered as GSK pursued ‘egregious’ price hikes, senator says.. statnews.com/pharmalot/20... #pharma #asthma #medicines #patents #GSK

Pharmalittle: We're reading about obesity pill trial results, cholesterol guidelines, and more Structure Therapeutics disclosed that its daily obesity pill led patients to lose about 16% of their body weight relative to placebo after 44 weeks

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about obesity pill trial results, cholesterol guidelines, and more news.. statnews.com/pharmalot/20... #pharma #obesity #cholesterol #RSV #vaccines #GSK #JNJ #CVS

GSK's RSV shot cleared in US for all adults GSK is back on level pegging with its rivals in the RSV vaccine category in the US, after getting FDA approval for Arexvy in the 18 to 49 age bracket.

#GSK is back on level pegging with its rivals in the #respiratorysyncytialvirus (RSV) vaccine category in the #US, after getting #FDAapproval for the 18 to 49 age bracket.

pharmaphorum.com/news/gsks-rs...

GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk GSK (NYSE: GSK) announced that the FDA expanded AREXVY's approved US indication to include adults aged 18–49 years at increased risk for RSV-related lower respiratory tract disease (LRTD). The decision (March 13, 2026) cites Phase IIIb non-inferior immune responses and prior efficacy and safety data.The release notes annual US burden estimates for 18–49-year-olds: ~17,000 hospitalizations, 277,000 ED admissions and 1.97 million outpatient visits, and reiterates common, mostly short-lived adverse events.

#GSK GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

www.stocktitan.net/news/GSK/gsk-s-rsv-vacci...

En başarılı Türk takımı, önümüzdeki Çarşamba günü Liverpool'un Avrupa'daki hegemonyasını kırabilecek mi?

⚽👏❤️💛

#UCL #GALLIV #GSK

Liverpool's early error has handed Galatasaray a 1-0 advantage at home. With the fans behind them, Galatasaray will be aiming to press their lead and secure a spot in the #UCL QFs. Can the the most successful Turkish bring down Liverpool's European curtain next Wednesday?

⚽👏❤️💛

#GALLIV #GSK

GSK Reaches Settlement in Class Action Lawsuit Over BOOSTRIX Vaccine Advertising Claims The class action lawsuit against GSK regarding BOOSTRIX vaccine misleading advertising has led to a proposed settlement, providing compensation to eligible claimants.

GSK Reaches Settlement in Class Action Lawsuit Over BOOSTRIX Vaccine Advertising Claims #United_States #New_York #Class_Action #GSK #BOOSTRIX

Large drugmakers are developing fewer antibiotics, analysis finds The number of potential antimicrobial treatments being developed by the world’s largest drugmakers nosedived by 35% over the past five years, according to a new analysis.

Large drugmakers are developing fewer and fewer antibiotics.. statnews.com/pharmalot/20... #pharma #medicines #antibiotics #antimicrobials #GSK

#GSK has signed an eleventh-hour agreement to give #Alfasigma rights to its #primarybiliarycholangitis (PBC) therapy linerixibat, which is under #regulatoryreview in most major pharma markets #worldwide.

buff.ly/TotgbnR

UK companies in the news:

#ADVT #BSRT #CKN #CRDL #FXPO #GPM #GSK #HEX #HGT #KETL #MMIT #NRR #SAA #STS

Head to Sharesify.com for news, views and analysis.

Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Up and Down the Ladder: Job Changes.. the latest comings & goings.. recognize anyone? statnews.com/pharmalot/20... #pharma #biotech #jobs #GSK #AbbVie #Takeda #AstraZeneca

No wonder she's smiling like Patrick Bateman's sister.

#GSK #CEOPay @highpaycentre.bsky.social

#r4today

【GSKのRSVワクチン「Arexvy」、欧州で18歳以上の成人全体へ適応拡大】

欧州委員会（EC）は、GSKのアジュバント添加組換えRSVワクチン「Arexvy」について、18歳以上の成人全体への使用を承認した。

✔ 従来の「60歳以上」および「50〜59歳の高リスク群」から対象を拡大
✔ 欧州各国が成人全体への接種提供を検討できる枠組みが成立
✔ EUでは毎年平均15万8000人の成人がRSV関連疾患で入院と報告

#RSV
#ワクチン
#GSK

More Acquisitions: #QuantumeMotion > #SKVTechnology; #Salesforce > #Momentum; #Scale > #Reload; #Brink’s > #NCRAtleos

Agreed Acquisitions: #Arcellx > #GileadSciences; #DubaiAerospaceEnterprise > #MacquarieAirFinance; #Engie > #UKPowerNetworks; #GSK > #35Pharma; #Uber > #SpotHero

UK companies in the news:

#ANG #CSSG #CVSG #DLN #EAH #EMG #FDEV #GNS #GPE #GSK #HDD #HIK #HWDN #JMGI #JSE #JUP #LSEG #MACF #MCG #MTEC #NEXS #OCDO #PIN #PLSR #PPHE #RR. #SAV #SEPL #SREI #TATE #UKW #VANQ #WIL #WPP

Head to Sharesify.com for news, views and analysis.

GSK grows pipeline with 35Pharma takeover, Frontier deal GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.

The steady stream of M&A #deals in #pharma this year has continued with the news that #GSK has agreed to buy #Canada's #35Pharma and its drug candidate for #pulmonaryhypertension (PH) for $950 million.

Pharmalittle: We're reading about Trump's drug-price claims, a Novo deal for obesity drugs, and more In his State of the Union address, President Trump claimed he had brought U.S. prescription drug costs from the highest in the world to the lowest

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about Trump’s drug-price claims, a Novo deal for obesity drugs, and more news.. statnews.com/pharmalot/20... #pharma #Trump #obesity #Medicare #antibiotics #Novartis #novonordisk #GSK

Frontier Biotech Enters Exclusive Licensing Deal with GSK for siRNA Therapeutics In a significant move, Frontier Biotech has partnered with GSK, securing exclusive global rights to develop two innovative siRNA therapeutics.

Frontier Biotech Enters Exclusive Licensing Deal with GSK for siRNA Therapeutics #USA #Nanjing #GSK #siRNA #Frontier_Biotech

UK companies in the news:

#ABF #AFC #ADVT #AML #AUGM #AVG #BGEO #DGE #GLB #GSK #HLN #HMSO #HSBA #HSX #IGET #IPF #JET2 #MEGP #MGNS #OMG #PTAL #SHC #STJ #TRCS #VIC

Head to Sharesify.com for news, views and analysis.

Frontier Biotech and GSK Join Forces in Global Licensing Agreement for siRNA Therapies Frontier Biotech has secured an exclusive global licensing agreement with GSK for the development of innovative siRNA therapies, marking a significant milestone.

Frontier Biotech and GSK Join Forces in Global Licensing Agreement for siRNA Therapies #China #Nanjing #GSK #siRNA_therapies #Frontier_Biotech

GSK、テリルジー・エリプタを中国で喘息に適応追加──成人のコントロール不良喘息で承認、CAPTAIN第3相のFEV1改善を整理 | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

GSK、テリルジー・エリプタを中国で喘息に適応追加──成人のコントロール不良喘息で承認、CAPTAIN第3相のFEV1改善を整理
Trelegy Ellipta approved in China for the maintenance treatment of asthma

stellanews.life/technology/8...

#Asthma #COPD #TrelegyEllipta #GSK #NMPA #TripleTherapy #RespiratoryCare

【GSK、中国でテリルジーの喘息適応追加承認を取得】

GSKは、中国国家薬品監督管理局（NMPA）より、3剤配合吸入剤「テリルジー・エリプタ（フルチカゾンフランカルボン酸エステル／ウメクリジニウム／ビランテロール）」の成人におけるコントロール不良喘息への適応拡大承認を受けた。

✔ 喘息とCOPDの両疾患に対応する初の単一吸入3剤併用療法
✔ 第3相CAPTAIN試験に基づき、肺機能指標FEV1の有意な改善を確認
✔ 1日1回の吸入で、既存治療で不十分な患者の新たな選択肢に

#喘息 #GSK #テリルジー #呼吸器疾患 #中国医療

Frontier Biotech Teams Up with GSK for Exclusive RNA Therapy Licensing Agreement Frontier Biotech has entered a major exclusive licensing agreement with GSK for developing two innovative small interfering RNA therapies, marking a significant milestone.

Frontier Biotech Teams Up with GSK for Exclusive RNA Therapy Licensing Agreement #USA #Nanjing #GSK #RNA_Therapy #Frontier_Biotech